Anlon Healthcare Limited has announced a significant development in its product portfolio, revealing the successful creation of two new anti-malarial products. The company, known for its pharmaceutical innovations, is set to introduce Artemether and Lumefantrine to the market in November 2025.

Product Development

The announcement comes as part of Anlon Healthcare's strategic initiative to expand its product range and address the evolving needs of its clientele. The two new products, both targeting malaria treatment, represent a notable advancement in the company's research and development efforts:

• Artemether: An anti-malarial medication
• Lumefantrine: Another anti-malarial drug

Launch Timeline

According to the company's official communication to the stock exchanges, both Artemether and Lumefantrine are scheduled for launch in November 2025. This timeline gives Anlon Healthcare ample opportunity to prepare for the market introduction and potentially set the stage for a strong entry into the anti-malarial segment.

Strategic Implications

The development of these new products aligns with Anlon Healthcare's broader strategy to diversify its offerings and strengthen its position in the pharmaceutical market. By focusing on anti-malarial medications, the company is addressing a critical global health concern, potentially opening up new market opportunities.

Regulatory Compliance

In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Anlon Healthcare has duly informed the stock exchanges about this significant development. The company has stated that it will provide further updates on these products as developments occur.

Management Statement

Punitkumar Rasadia, Managing Director of Anlon Healthcare Limited, signed off on the regulatory filing, underlining the importance of this announcement to the company's growth trajectory.

Investors and stakeholders will be keenly watching for further updates on these new products as Anlon Healthcare moves closer to the projected launch date.

Anlon Healthcare Limited has recently disclosed a significant change in its shareholding structure, following the acquisition of equity shares in the company. This development was reported in compliance with Regulation 29(2) of the Securities and Exchange Board of India (SEBI) Substantial Acquisition of Shares and Takeovers Regulations, 2011.

Regulatory Compliance

The company has duly notified both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) about this change in shareholding. This move aligns with the company's commitment to transparency and adherence to regulatory requirements.

Disclosure Details

According to the LODR (Listing Obligations and Disclosure Requirements) data, the disclosure was made on September 13. The document was signed by Punitkumar Rasadia, the Managing Director of Anlon Healthcare Limited, emphasizing the company's adherence to corporate governance standards.

Company Information

Anlon Healthcare Limited, with its Corporate Identification Number (CIN) U24230GJ2013PLC077543, has its registered office at 101/102, Silver Coin Complex, opposite Crystal Mall, Kalawad Road, Rajkot- 360005, Gujarat, India. The company can be reached at +91-7069690081/82 or via email at info@anlonhealthcare.com .

While the specific details of the shareholding change were not provided in the available data, such disclosures are typically made when there is a substantial acquisition or change in the ownership structure of the company. Investors and stakeholders are advised to refer to the detailed disclosure document for more information on the nature and extent of the shareholding change.

This development may be of interest to current shareholders, potential investors, and market analysts monitoring the healthcare sector. As always, it is recommended that interested parties conduct their own due diligence and consult with financial advisors before making investment decisions based on this information.